It has been claimed by Whitby (1) that sulfapyridine saved a majority of mice infected intraperitoneally with 10,000 fatal doses of pneumococci of Types I, II, III, V, VII, and VIII, its therapeutic efficacy being more pronounced against Types I, VII, and VIII. Furthermore, mice which recovered by virtue of this presumably nontoxic drug were immune to a second infection of 10,000 and in some instances 1,000,000 fatal doses of pneumococci as early as the end of the first week.
The announcement of this experimental work was quickly followed by the clinical report of Evans and Gaisford (2) who claimed a reduction in mortality from 27 in 100 untreated cases of pneumonia to 8 in 100 who received sulfapyridine. These two papers are responsible for the present intense interest in sulfapyridine as an antipneumococcic drug.
A comparison of the efficacy of sulfapyridine and sulfanilamide by Cooper, Gross, and Lewis (3) against Type II pneumococcic infections of less than 100 fatal doses in both mice and rats showed the former compound slightly more effective than the latter, although approximately one-half of the animals in the treated groups died.
In a simultaneous publication, Hilles and Schmidt (4) reported sulfapyridine not significantly superior to sulfanilamide against mouse infections of 100 fatal doses of Type XXII pneumocci. Unfortunately, the results obtained are not comparable because different dosages of the two drugs were administered by two different methods. Although sulfapyridine prolonged the lives of all 20 mice, 9 living 6 days or longer, all but one died before the fifteenth day. Similarly, in the sulfanilamide group, most of the mice died after the sixth day and all by the thirteenth day. In a subsequent experiment, 14 of 20 mice which received 80 mgm. of sulfapyridine orally each day for 4 days, then 40 mgm. daily for 2 days, survived 30 days. A comparable sulfanilamide experiment was not recorded.
Long, Bliss, and Feinstone (5), on the other hand, concluded that sulfapyridine was considerably more effective than sulfanilamide in the treatment of experimental Type I infections of mice. These conclusions were based on a 12 per cent survival in the sulfapyridine group and no survivors in the sulfanilamide group, both of which were infected with approximately 1180 fatal doses.
Because of the lack of agreement between Whitby's (1) and our own (3) results, experimental work has been continued and the comparative efficacy of sulfapyridine, sulfanilamide, and specific antipneumococcic rabbit serum determined against Type III pneumococcic meningitis and pneumonia of rats as well as septicemia of mice.
The immunity of the recovered animals from this and from a preceding experiment (3) was determined by the intraperitoneal inoculation of 1 and also of 100 fatal doses of homologous culture.
The purpose of the following report is to present the data from this study.
Pneumococcic meningitis of rats
Method. Six groups of 15 rats each were infected intracranially (3, 6, 7, 8) The immunity of the rats which survived for one month was determined by infecting them intraperitoneally with approximately one fatal dose, determined by intraperitoneal titration, of the same Type III strain.
Results. As shown in Figure 1 , all untreated rats died in 2 days and all serum-treated rats within 5 days. The sulfanilamide-and sulfapyridine-treated groups suffered a mortality of 3 and 8; the sulfanilamide plus serum and sulfapyridine plus serum groups, 5 and 11 of 15 rats respectively. It is significant that of the 75 rats which received some form of treatment, 6 died late in the experiment of a relatively fresh meningitis.
Of the 32 rats which recovered from meningitis as a result of treatment, 22 Pneumococcic pneumonia of rats Method. Four groups, each of 15 rats, were infected intratracheally, as described in previous experiments (9, 10, 11, 12) with a mucin suspension of approximately 100 fatal doses of Strain 420 Type III pneumococci. One group received no treatment, whereas the remaining 3 groups were treated with sulfanilamide, sulfapyridine, and Type III antipneumococcic rabbit serum as shown in Figure 2 .
Results. Reference to Figure 2 shows that all control rats died in 2 to 10 days after infection, whereas the mortality of the sulfanilamide, sulfapyridine, and serum-treated groups was 6, 9, and 7 of 15 respectively one month later. All fatalities, except four in the sulfapyridine group, showed at autopsy the type of experimental pneumonia previously described. Bacteremia, as demonstrated by culture from the femoral vein at autopsy, was present in all control and sulfanilamide-treated rats, but was absent in several serum-treated rats and several treated with sulfapyridine.
In this experiment, as in the preceding one, there were a number of delayed deaths, 5 of which occurred in the sulfanilamide group from 11 to 16 days and one in the sulfapyridine group 9 days after infection.
The immunity of the pneumonia survivals was considerably greater than that of the meningitis survivals since there were only 4 deaths out of 18 survivors distributed as follows: 1 of 8 in the sulfanilamide, 3 of 4 in the sulfapyridine, and none of 6 in the serum group; whereas 11 of 14 normal control rats died.
Pneumococcic septicemia of mice Method. Four groups, each of 10 mice, were infected subcutaneously with more than 100 fatal doses of the same 420 strain. (Titration mice which received %0 and Moo of the infecting dose used in the experiment died within 72 hours.) One group served as untreated controls, while the remaining groups were treated as shown in Table   I .
Results. The mortality rates of the various groups were: controls, 10; sulfanilamide, 9; sulfapyridine, 5; and serum, 5 of 10 mice.
Since the number of survivals from this experiment was too small to be statistically significant, the survivals from some unreported mouse experiments were reinfected intraperitoneally with 100 fatal doses of the homologous Type II (Binda) culture. Reference to Table II (13, 14) and to type (4) differences, both the experimental work and the cures of clinical pneumococcic meningitis point to strain difference as the more important factor. This view is strengthened by our experience with 3 Type II strains which show marked differences in invasive power and in response to chemotherapy. However, experimental results show that neither sulfapyridine nor sulfanilamide is effective against pneumococcic infections of mice or rats when the infection exceeds 100 fatal doses. This statement receives added support from the results of experiments (15) in which mice were infected with approximately 100 lethal doses of Type II pneumococci and treated 4 hours later. An aggregate of 80 mice treated with sulfapyridine suffered a 55 per cent mortality while an equal number of mice treated with an equal dosage of sulfanilamide showed a 74 per cent mortality at the end of 3 weeks. Hilles and Schmidt (4) obtained similar results in mice treated with 4 grams per kilo the first day, followed by 5 daily treatments of 1 gram per kilo; but saved 14 out of 20 mice when 4 grams per kilo were given for 4 days and 2 grams per kilo for 2 additional days.
In view of the discrepancy between the results so far reported and Whitby's (1) claim that sulfapyridine saved a majority of mice infected with 10,000 fatal doses of pneumococci, a further consideration of the method whereby such favorable results were obtained appears indicated. In Whitby's various publications (1, 16, 17) , the therapeutic efficiency of each drug under investigation was expressed by a figure designated as the "survival value." This figure represented the average survival time of groups of mice, usually 6 in number, which were observed in most instances for 7 days. This simple method of evaluation is open to question since it ignores ultimate survivals and may give the same value, such as 5 out of a possible 7, in experiments which produce quite different end results. For example, a value of 5 would be obtained in an experiment in which one-half of the mice survived indefinitely, while 1 of each of the remaining 3 died at the end of the second, third, and fourth days. Similarly, a value of 5 would be obtained if all mice died at the end of the fifth day or if 2 died at the end of each of the fourth, fifth, and sixth days, leaving in the last 2 instances no survivors. The 7-day period of observation, considered adequate by Whitby (1, 16, 17, 18) was found to be insufficient by others who observed a significant number of deaths between the second and fourth weeks of observation (3, 4, 9, 10, 12, 19, 20, 21 ).
Another circumstance which throws doubt upon the validity of this method of evaluation is the difference in values which the author reported for sulfanilamide against Type I infections: 1.2 out of a possible 7 in 1937 (18) and 3.3 out of 7 in 1938 (1).
It is evident from Experiment I that sulfanilamide and sulfapyridine are about equally effective in treating Type III experimental meningitis, whereas Type III rabbit antipneumococcal serum was valueless. However, in Experiment II all three medications appeared equally effective, in the dosages employed, against pneumococcic pneumonia. This latter observation is confirmatory of previous conclusions concerning the therapeutic value of sulfanilamide and specific antiserum in experimental Type I (10) and Type II (12) pneutnococcic pneumonia and Type I pneumococcic meningitis (8) .
The serum dosage was calculated on a weight for weight basis from a human dosage of 350,000 units for Experiment I, one and one-half times that amount for Experiment II, and three times the amount for Experiment III.
The dosage of sulfanilamide employed throughout was that which has consistently given good results in our hands (6, 7, 9, 10, 11, 12) . The fact that this dosage of 0.5 to 1.0 gram per kilo of rat is, weight for weight, considerably more than the 0.08 to 0.15 gram per kilo generally advocated for man (22) , has occasionally prevented the casual observer from recognizing the clinical application of the animal experiments. For example, the Pneumonia Commission of the Medical Society of the State of Pennsylvania (23) was of the opinion that the amount of sulfanilamide required for adequate treatment of clinical pneumonia, calculated from the quantity used in animals, was so great as to be dangerous. Marshall and Cutting (24) have subsequently shown such fears to be groundless since only a fraction of the dose which is required to maintain the therapeutically effective concentration of 5 to 15 mgm. per cent in the rat is necessary to produce the same optimum blood level in man. In the mouse, however, 1.0 gram per kilo produced the high concentration of approximately 50 mgm. per cent during the first 2 hours, 20 to (24) . From this it is evident that the rat is the experimental animal of choice, not only because of the ease in producing the pneumococcic diseases most frequently encountered in humans, namely pneumonia and meningitis, but, because daily or twice daily treatments produce blood concentrations of sulfanilamide of the same order as those considered optimum in clinical practice. Furthermore, the validity of the results obtained experimentally in rats is being substantiated by the rapidly accumulating reports of clinical cures of both pneumococcic pneumonia and meningitis (8) .
The high degree of immunity which Whitby (1) claimed followed the recovery of sulfapyridine-treated mice was absent in our series of meningitis and pneumonia rats which received sulfapyridine. In fact, these rats showed numerically less immunity than those treated with sulfanilamide or serum when reinfected with one or ten carefully titrated fatal doses of homologous culture. It would also appear that late deaths would have been less frequent in both series if a significant degree of immunity had followed treatment and apparent recovery. In regard to the immunity of recovered mice, Feinstone et al. (25) observed none in those which had received 4,4'-diaminodiphenylsulfone, when reinfected 30 days later with 10 to 100 fatal doses. Although our mice showed a certain degree of immunity, it did not approach that claimed by Whitby (1) 
